Amgen’s Repatha Included in Updated PCSK9 Protocol
- Document date
- Apr 17, 2024
The 30-second brief
An addendum to the PCSK9 inhibitors protocol was recommended, supporting Medicaid reimbursement for Amgen’s Repatha (evolocumab).
AMGEN holds this supplies contract with Department of Human Services | State of New Jersey. Its other public contracts on record include work for Conejo Academy of Leadership and Language Immersion and University Of Wisconsin-System Administration.
See every contract and contact at Department of Human Services | State of New Jersey.
See every contractFree account · 30-second setup · No credit card
Contract details
- Contract type
- Supplies
- Document date
- April 17, 2024
- Vendor
- AMGEN
- Source document
- nj-department-of-human-services-agenda-2024-04-17_e97.pdf (Agenda)
AMGEN's other public contracts
More Department of Human Services | State of New Jersey contracts
Questions about this contract
Who was awarded the supplies contract by Department of Human Services | State of New Jersey?
AMGEN was awarded this supplies contract by Department of Human Services | State of New Jersey, as recorded on April 17, 2024.
What type of contract is this?
This is a Supplies contract, documented as a agenda record.
Where was this contract approved?
This contract appears in nj-department-of-human-services-agenda-2024-04-17_e97.pdf (Agenda), dated April 17, 2024 from Department of Human Services | State of New Jersey. Civic IQ extracts contract records directly from agency meeting documents and solicitations.
What other contracts does AMGEN hold?
AMGEN may hold additional government contracts. View their full contract history, the agencies they serve, and total tracked spend on their Civic IQ vendor profile.
Show 1 more question
What is Department of Human Services | State of New Jersey currently buying?
Explore Department of Human Services | State of New Jersey's vendors, signed contracts, and active RFPs on their Civic IQ agency profile.